Abstract
Binding of cellular ?-dystroglycan (?-DG) to its extracellular matrix ligands is fully dependent on a unique O-mannose-linked glycan. Disrupted O-mannosylation is the hallmark of the muscular dystrophy-dystroglycanopathy (MDDG) syndromes. SLC35A1, encoding the transporter of cytidine 5'-monophosphate-sialic acid, was recently identified as MDDG candidate gene. This is surprising, since sialic acid itself is dispensable for ?-DG-ligand binding. In a novel SLC35A1-deficient cell model, we demonstrated a lack of ?-DG O-mannosylation, ligand binding and incorporation of sialic acids. Removal of sialic acids from HAP1 wild-type cells after incorporation or preventing sialylation during synthesis did not affect ?-DG O-mannosylation or ligand binding but did affect sialylation. Lentiviral-mediated complementation with the only known disease mutation p.Q101H failed to restore deficient O-mannosylation in SLC35A1 knockout cells and partly restored sialylation. These data indicate a role for SLC35A1 in ?-DG O-mannosylation that is distinct from sialic acid metabolism. In addition, human SLC35A1 deficiency can be considered as a combined disorder of ?-DG O-mannosylation and sialylation, a novel variant of the MDDG syndromes. ? The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Original language | English |
---|---|
Pages (from-to) | 2241-2246 |
Journal | Human Molecular Genetics |
Volume | 24 |
Issue number | 8 |
DOIs | |
Publication status | Published - 15 Apr 2015 |